Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Orforglipron

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity

Eli Lilly · Phase 3 · Active, not recruiting · Enrollment 800

NCT06972459

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Orforglipron Dose 1n/rn/rn/rn/r
Orforglipron Dose 2n/rn/rn/rn/r
Orforglipron Dose 3n/rn/rn/rn/r
Orforglipron Dose 4n/rn/rn/rn/r
Placebon/rn/rn/rn/r

Not shown

  • Orforglipron Dose 1: endpoint not reported
  • Orforglipron Dose 2: endpoint not reported
  • Orforglipron Dose 3: endpoint not reported
  • Orforglipron Dose 4: endpoint not reported
  • Placebo: endpoint not reported